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(Akira et al., 2006). Innate immunity relies on the binding of PAMPs to
receptors on immune cells and to serum proteins, such as mannose-
binding lectin (Akira et al., 2006; Ip et al., 2009). Cartwright et al. devel-
oped an ELISA using an engineered immunoglobulin domain fused to
domains of mannose-binding lectin. This protein binds carbohydrateDetermining whether a patient has a microbial infection is a com-
mon clinical challenge. Sepsis is a case in point where clinical signs
may be confused with causes other than infection, such as trauma. In
this issue of EBioMedicine, Cartwright et al. describe a rapid blood test
to discriminate between patients with microbial infections and those
with sterile trauma (Cartwright et al., 2016). This is a ground-breaking
and much-needed development.
Sepsis is the most common cause of death in hospitalized patients,
with an estimated 200,000 deaths annually in the USA (Deutschman
and Tracey, 2014). However, sepsis is an imprecise clinical syndrome,
with a variable clinical presentation (Angus and van der Poll, 2013). Di-
agnosis is usually based on suspicion of infection, combined with signs
of organ dysfunction (Cohen et al., 2015). Early diagnosis of sepsis and
administration of antibiotics is vital because progression to severe sep-
sis or septic shock has serious consequences (Angus and van der Poll,
2013). Unfortunately, differentiating between sepsis and other inﬂam-
matory conditions is often challenging in seriously ill patients. Detecting
bacterial infections in blood is a key step in the diagnosis of sepsis, and
initiating treatment with antimicrobials (Deutschman and Tracey,
2014; Cohen et al., 2015). However, blood cultures are negative in 60
to 70% of patients with severe sepsis (Cohen et al., 2015), and N80%
were negative in the study by Cartwright et al. (2016). In addition, mi-
crobiology takes too long to inﬂuence ﬁrst line therapy against patho-
genic bacteria. Developments in PCR and mass spectrometry have
increased the likelihood of identifying bacteria in blood samples, but
often rely on time-consuming pre-analytical processing such as blood
culture in order to increase pathogen load. Proxies for infection include
increased circulating cytokines and acute phase proteins, such as C-re-
active protein; although, their concentrations also increase during phys-
iological events such as parturition, or pathological tissue damage such
as burns.om.2016.06.014.
. This is an open access article underPathogen-associated molecular patterns (PAMPs) are molecules
found in prokaryotes, such as bacteria and fungi, but not in animals
PAMPs, including lipopolysaccharide and lipoteichoic acid, from a
wide range of Gram-negative and Gram-positive bacteria, and mannan
from fungi (Kang et al., 2014). The ELISA detected PAMPs from live or
dead pathogenic bacteria in whole blood (Cartwright et al., 2016). Ani-
mal studieswere used to demonstrate the utility of the assay for detect-
ing PAMPs, even when blood cultures were culture-negative, during
antimicrobial treatment, orwhen the initial infectionwas intraperitone-
al. The ELISA was then evaluated in human patients, and had greater
speciﬁcity than C-reactive protein in differentiating between infection
and trauma. In addition, the assay detected PAMPs in 80% of blood sam-
ples from emergency department patients with infection-related dis-
eases and suspected sepsis, even though b20% had positive blood
cultures (Cartwright et al., 2016).
The ELISA developed by Cartwright et al. has several beneﬁts over
current diagnostics for infections. First, the assay detects pathogenmol-
ecules, even in patients treated with antimicrobials, which often yield
negative blood-cultures. Furthermore, the ELISA can be completed
within an hour using whole blood, rather than N24 h often necessary
for blood culture (Cohen et al., 2015). Although PCR-based assays are
useful when living bacteria are present in blood, the present ELISA
also detects PAMPs released during tissue infections even when blood
cultures do not detect live pathogens. However, adoption of the ELISA
will likely be contingent on large trials to test the predictive value in pa-
tient populations with suspected sepsis. Conversely, one wonders
whether other assays could be developed to aid the diagnosis of non-in-
fectious trauma, perhaps by detecting damage-associated molecular
patterns released by dying or damaged cells (Chen and Nunez, 2010).
Beyond sepsis, overprescribing antibiotics and the rise of antimicro-
bial resistance is of considerable concern. The O'Neill report, which pro-
vides recommendations for tackling drug-resistant infections globally,
advises developing diagnostics for bacterial infections to guide the use
of antimicrobials (O'Neill, 2016). So, the ELISA described by Cartwright
et al. is a welcome step forward to help direct therapy toward patients
with bacterial infections. The use of antimicrobials in animals is another
concern of the O'Neill report (O'Neill, 2016), and a test for bacterial in-
fection might also ﬁnd utility with veterinarians to justify the use ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
14 I.M. Sheldon / EBioMedicine 9 (2016) 13–14antibiotics, especially as the ELISA works in animal models (Cartwright
et al., 2016). The ELISAmight also be engineered tomake a point-of-care
assay, facilitating rapid patient treatment, and applicable for emergency
care in the ﬁeld or in developing countries. However, as the ELISA is
non-speciﬁc, it might need to be paired with molecular diagnostic as-
says that identify species of bacteria, and perhaps their antimicrobial re-
sistance genes, to best inform the selection of antimicrobials.
In summary, the ELISA developed by Cartwright et al. (2016) pro-
vides the potential to use whole blood for the rapid detection of infec-
tions. Translation of this technology for use in clinical practice will
beneﬁt the diagnosis of sepsis. Beyond sepsis diagnosis, the work may
heraldmethods tomeet the clinicians' dreamof discriminating infection
from sterile inﬂammation.
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